Seal Rock's ASK1 inhibitor improves NASH symptoms in mice

Seal Rock Therapeutics Inc. (Seattle, Wash.) said lead candidate SRT-015 significantly improved metabolic parameters and liver-specific pathology in a mouse model of non-alcoholic steatohepatitis (NASH). The liver-selective apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) inhibitor also significantly reduced hepatomegaly, liver fibrosis, steatohepatitis and inflammation. Data will be presented at January's Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting in Santa Fe.

The company said it is proceeding with IND-enabling activities for SRT-015...